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Extended-spectrum
β β-Lactamase-
producing Flora in
Healthy Persons 
To the Editor: Extended-spectrum
β-lactamase (ESBL)–producing
gram-negative bacilli are endemic in
hospitals. In intensive care units, 2%
prevalence of ESBL-producing
organisms has been reported (1).
Exceedingly high rates of ESBL-pro-
ducing bacteria in Indian hospitals
prompted us to look at the fecal car-
riage of ESBL in the community (2).
One hundred healthy executives
received a comprehensive health
check at our tertiary care center in
central Mumbai from August to
September 2004. The predominant
isolates from stool samples obtained
for routine examination were cul-
tured, and initial screening for ESBL
production was conducted by using
the disk diffusion method according
to NCCLS guidelines (3). For these
isolates, the ESBL phenotypic confir-
mation was performed with cef-
tazidime-clavulanate for an increase
in zone diameter by 5 mm (disk
potentiation). In addition, the ATB
BLSE strip (bioMérieux, Lyon,
France) was used to confirm the pres-
ence of inhibitor (sulbactam)-suscep-
tible enzymes and to differentiate the
strains from those that were either
inhibitor resistant or harboring other
β-lactamases, such as those of AmpC
derivation. The ATB BLSE strip con-
sists of a varying concentration of cef-
tazidime, 0.5–32 mg/L, and aztreon-
am, 0.5–8 mg/L, with varying combi-
nations of these agents with a β-lacta-
mase inhibitor, i.e., + sulbactam,
0.06–1 mg/L. Cefotetan (4 and 32
mg/L) and imipenem (4 and 8 mg/L)
were also included in the strip. The
test was considered positive when a
variation of >4 dilutions was observed
between the antimicrobial agent test-
ed alone and the agent combined with
the inhibitor. Eleven of the 100 sam-
ples screened were positive for
ESBL-producing Escherichia coli and
Klebsiella pneumoniae. Seven of the
11 were confirmed by using the ATB
BLSE strip. The MIC of ceftazidime
and aztreonam in all 7 isolates was
8 µg/mL. We might be underreporting
ESBL producers in these cases by not
including the cefotaxime-clavulanate
combination in addition to the cef-
tazidime-clavulanate concentration.
The percentage resistance to
ciprofloxacin was 45%. All isolates
were susceptible to amikacin and the
carbapenems. None of the executives
gave a history of hospitalization in the
last year or history of antimicrobial
drug consumption in the last 6
months.
This trend in patients with no
apparent risk factors for ESBL car-
riage calls for urgent attention.
Unknown environmental factors are
likely playing a key role in maintain-
ing this selective pressure. Larger
studies are required to substantiate
these findings. 
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Measuring Impact
of Antimicrobial
Resistance
To the Editor: Staphylococcus
aureus and  Enterococcus faecium
commonly cause healthcare-associat-
ed bloodstream infections (BSI) in the
intensive care unit (ICU). Antimicro-
bial resistance is increasing in both
organisms. The impact of antimicro-
bial resistance on dying of BSI has
been studied extensively (1,2). Many
studies have concluded that BSI
caused by an antimicrobial-resistant
organism results in higher death rates
(1,3–8). However, as discussed in a
recent report by Kaye et al., “outcome
studies of antimicrobial drug resist-
ance are notoriously hard to perform
because of confounding variables
related to coexisting conditions” (9).
Indeed, almost all studies have shown
that infections with antimicrobial-
resistant organisms occur later in hos-
pitalization than infections with
antimicrobial-susceptible organisms,
which suggests that differences in
death rates may be, at least in part,
caused by a difference in the patients’
underlying illnesses and protracted
hospital course. We report 2 addition-
al methodologic issues that can affect
estimates of the impact of antimicro-
bial resistance: combining different
organisms and combining populations
from different types of ICUs. 
The original objective of our mul-
ticenter observational study was to
quantify the clinical impact of antimi-
crobial resistance in S. aureus and E.
faecium infections when these bacte-
ria cause a specific type of infection: a
monomicrobial, ICU-attributable,
central vascular catheter–associated
bloodstream infection (CVC-BSI).
We studied 187 adult ICU patients
with BSI caused by S. aureus and E.
faecium at 3 tertiary care institutions
from 1994 to 1999. The institutional
review boards of each institution and
the Centers for Disease Control and
Prevention approved this study.
Severity of illness was measured with
an APACHE II score at ICU admis-
sion and on day 7 in the ICU (if appli-
cable). The score would indicate the
patient’s risk of dying in the hospital
before a BSI developed by using a
measure validated for predicting in-
hospital deaths in ICU patients (10).
The study population stratified by
organism is shown in the Table. Fifty-
eight percent of patients had CVC-
BSI with S. aureus, and 42% had
CVC-BSI with E. faecium. Overall,
58% of the organisms causing CVC-
BSI were resistant to oxacillin if S.
aureus or to vancomycin if E. faeci-
um. However, patients with E. faeci-
um CVC-BSI were more likely to be
infected with antimicrobial-resistant
bacteria (69% versus 50%, p<0.01),
and had a higher mortality rate (54%
versus 34%, p<0.01) than patients
with S. aureus CVC-BSI. This finding
indicates that the type of organism (E.
faecium versus S. aureus) confounds
the association between resistance
and death. In addition, the distribution
of ICU type by organism varies,
which suggests that patient popula-
tions infected with these 2 different
organisms were different in other
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